Rémi Droller

Rémi Droller is Member of the Management Board of Kurma Partners. Master in molecular biology (Paris VI) and Master in finance and innovation management (Masternova - AgroPariTech).

First at CDC Innovation between 2000 and 2003, he then joined AGF Private Equity (now Idinvest Partners) where he developed the investment activity in life sciences and made investments such as Novagali Pharma (listed on Euronext and acquired by Santen), Prosensa Therapeutics (listed on Nasdaq and acquired by Biomarin), Vivacta (acquired by Novartis), Integragen (listed on Alternext), Onxeo (listed on Euronext).

Rémi joined Kurma Partners in 2010 and is in charge of investments in AM Pharma (Netherlands), Orphazyme (Denmark), Oxthera (Sweden), Stat Diagnostica (Spain), Step Pharma (France) and Zealand Pharma (Denmark) .